Form 4: Molina Healthcare Director Richard Zoretic Acquires Shares Under Equity Incentive Plan

Director Richard C. Zoretic acquired 189 shares of Molina Healthcare, Inc. common stock on January 1, 2025, as part of the company's 2019 Equity Incentive Plan.

Summary

• Richard C. Zoretic, a director at Molina Healthcare, Inc., acquired 189 shares of common stock on January 1, 2025.
• The acquisition was made under the company's 2019 Equity Incentive Plan as part of his compensation for serving as a director.
• The shares were granted at a price of $291.05, based on the closing price of Molina Healthcare's common stock on December 31, 2024, since January 1, 2025, was a non-trading day.
• The grant is part of an annual equity award to each director valued at $220,000, with one quarter ($55,000) granted each quarter.
• Following the transaction, Zoretic directly or indirectly beneficially owns 6,997 shares.
• The shares are held by the Richard Charles Zoretic Revocable Living Trust.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to positively as it aligns interests. There are no indications of negative sentiment.

Positives

• The equity incentive plan aligns the interests of directors with those of shareholders.
• Director's compensation includes equity, demonstrating a long-term commitment to the company's success.

Industry Context

Equity compensation is a common practice in publicly traded companies to align the interests of directors and management with shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the healthcare industry, but equity grants are a standard component.
• Companies like UnitedHealth Group and Anthem also utilize equity-based compensation for their directors.
• The specific amount and vesting schedules can differ based on company size, performance, and industry benchmarks.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with company performance.
• The transaction has no material impact on employees, customers, suppliers, or creditors.

Key Dates